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Tobacco smoking is a major public health problem and several
preventive public health strategies have been implemented. How-
ever, smoking remains disproportionately prevalent among people
with psychiatric illness1,2 and this is often considered within the
mental health profession to be a secondary or deferrable treatment
goal to the control of the psychiatric illness. It is becoming
increasingly clear that smoking is not innocuous to mental health,
and may in fact aggravate mental illness or contribute to its onset.
On a neurobiological level, this may be related to the impact of
nicotine on monoamine neurotransmitter regulation, including
dopamine, via the diffuse cholinergic pathways.3 This may
underlie the circadian dysrhythmicity and hedonic dysregulation
in smokers,4 and may predispose to the development of mood
disorders. Smoking also has other systemic and metabolic
consequences that may likewise increase this vulnerability.
There is already evidence that smoking is a risk factor for
depression. Association data from cross-sectional studies5,6
support evidence from prospective studies to suggest that smoking
pre-dates the onset of depression.7,8 However, there is only limited
longitudinal data in the existing literature, and most longitudinal
studies have involved time frames under 2 years, which may not
be adequate to demonstrate the insidious effects of nicotine
dependence. In this epidemiological study, we investigated the
status of tobacco smoking as a risk factor for major depression
using not only cross-sectional data but also longitudinal data that
extend over a period of 10 years.
Method
Participants
This study is nested within the Geelong Osteoporosis Study, a
programme of research originally designed to investigate the
epidemiology of osteoporosis in Australian women, but recently
expanded to examine both psychiatric illness and non-psychiatric
diseases. The criterion for inclusion into the Geelong Osteoporosis
Study is women listed on the current Australian Commonwealth
electoral roll for the region known as the Barwon Statistical
Division and the criteria for exclusion are inability to provide
informed consent, death, and not able to be contacted. Reasons
for non-participation are described elsewhere.9 During the period
1994–1997, 1494 women recruited into the Geelong Osteoporosis
Study have been prospectively followed for a decade. At the time
of writing, a further 208 had been recruited during 2005–2007. A
total of 1043 women (aged 20–93 years) participated in a psychi-
atric assessment during the period 2004–2007, thus fulfilling the
inclusion criteria for this study. The Barwon Health Research
and Ethics Advisory Committee approved the study, and all
participants provided informed, written consent.
Data
Lifestyle practices including smoking, alcohol consumption,
habitual physical activity levels and exposure to disease were
self-reported. Smoking was recognised if individuals reported
regularly smoking more than one or two cigarettes per day for
at least 6 months, and recorded details of smoking included
frequency and period of exposure. Alcohol intake was recognised
if alcohol was consumed several times per week or every day.
Habitual physical activity was classified as active if participants
reported ‘moving, walking and working energetically and
participating in vigorous exercise’, otherwise they were classified
as sedentary. Cardiovascular disease included hypertension,
angina and coronary artery disease; diabetes encompassed both
types 1 and 2. Socio-economic status was ascertained using
Socio-Economic Index for Areas index scores based on census
data from the Australian Bureau of Statistics.10 These data were
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Background
Smoking is disproportionately prevalent among people with
psychiatric illness.
Aims
To investigate smoking as a risk factor for major depressive
disorder.
Method
A population-based sample of women was studied using
case–control and retrospective cohort study designs.
Exposure to smoking was self-reported, and major
depressive disorder diagnosed using the Structured Clinical
Interview for DSM–IV–TR (SCID–I/NP).
Results
Among 165 people with major depressive disorder and 806
controls, smoking was associated with increased odds for
major depressive disorder (age-adjusted odds ratio (OR)=1.46,
95% CI 1.03–2.07). Compared with non-smokers, odds for
major depressive disorder more than doubled for heavy
smokers (>20 cigarettes/day). Among 671 women with no
history of major depressive disorder at baseline, 13 of 87
smokers and 38 of 584 non-smokers developed de novo
major depressive disorder during a decade of follow-up.
Smoking increased major depressive disorder risk by 93%
(hazard ratio (HR)=1.93, 95% CI 1.02–3.69); this was not
explained by physical activity or alcohol consumption.
Conclusions
Evidence from cross-sectional and longitudinal data suggests
that smoking increases the risk of major depressive disorder
in women.
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used to derive an Index of Economic Resources (IER), which was
categorised into five groups, according to quintiles of IER for the
study region.
The Structured Clinical Interview for DSM–IV–TR Research
Version, Non-patient Edition (SCID–I/NP)11 was used to identify
women with a lifetime history of major depressive disorder and to
determine age at onset. Psychiatric interviews were conducted by
trained personnel.
Study designs
Case–control
Among 1043 women who underwent psychiatric assessment, 237
were diagnosed with major depressive disorder and 806 had no
history of major depressive disorder. Exposure to smoking was
recognised if smoking was practised prior to the onset of major
depression. Sixty-eight individuals were excluded because their
age at major depressive disorder onset was less than 20 years
(the minimum age for controls) and four were excluded because
it was unclear whether smoking pre- or post-dated major
depressive disorder onset. Thus, 165 individuals with major
depressive disorder and 806 controls were eligible for analysis in
this case–control study.
Retrospective cohort
Among 1043 women who underwent psychiatric assessment, a
decade of longitudinal data was available for 835. Based on
retrospective data, 164 were excluded because they had experi-
enced a major depressive disorder episode prior to baseline.
Among the 671 women aged 20–84 years with no history of major
depressive disorder at baseline and who were thus eligible for
analysis in this retrospective cohort study, 51 developed de novo
major depressive disorder and 620 remained major depressive
disorder-free during follow-up. Participants were classified as
smokers if they were current smokers at baseline, otherwise they
were classified as non-smokers.
Statistics
Statistical analyses were performed using Stata (version 9.0) and
Minitab (version 13). Standard descriptive statistics were used to
characterise the participants in each study.
In the case–control study, participants were selected as cases
(people with major depressive disorder) or controls (people with
no major depressive disorder), and exposure to smoking was
documented for each group. Logistic regression modelling was
performed to determine the association between smoking and
major depressive disorder. Age was defined as the age at major
depressive disorder onset for cases and age at baseline for
controls, and was categorised into age groups for analysis.
Smoking was investigated as a binary variable and was also
categorised into groups according to the average number of
cigarettes smoked per day (0, 410, 11–20, 420 cigarettes/day).
Age, socio-economic status, physical illness, physical activity and
alcohol consumption were tested in the models as potential
confounders and effect modifiers.
In the cohort study, participants with no history of
major depressive disorder at baseline were selected, categorised
as current smokers or not, and followed until a first major
depressive disorder episode or until the end of the follow-up
period. The effect of smoking on development of de novo major
depressive disorder was examined using multivariate Cox
proportional hazards regression analysis, using age as the time
axis. The proportional hazards assumptions were checked using
Schoenfeld residuals before and after adjusting for potential
confounding by socio-economic status, physical illness, physical
activity and alcohol consumption.
Results
Case–control study
Characteristics of the participants involved in the case–control
analysis are shown in Table 1. Participants with major depressive
disorder were younger and were more often smokers. Exposure
to smoking was documented for 73 of the 165 people with major
depressive disorder and for 269 of 806 controls. Prevalence of
smoking was thus greater among women with major depressive
disorder (0.44 (95% CI 0.37–0.52) v. 0.33 (95% CI 0.30–0.37),
P=0.008). Exposure to smoking increased the odds for major
depressive disorder (odds ratio OR=1.58, 95% CI 1.13–2.23,
P=0.008) and this association persisted, albeit attenuated, after
adjusting for age (age-adjusted OR=1.46, 95% CI 1.03–2.07,
P=0.031). Socio-economic status did not confound the associa-
tion between smoking and major depressive disorder (age- and
socio-economic status-adjusted OR=1.49, 95% CI 1.05–2.11,
P=0.026). Similarly, the association was not explained by a history
of self-reported cardiovascular disease or diabetes (adjusted
OR=1.47, 95% CI 1.04–2.09, P=0.030). Among the 342 smokers,
participants with major depressive disorder smoked more heavily
than those in the control group (median (interquartile range), 15
(10–20) v. 10 (8–20) cigarettes per day, P=0.059). Compared with
non-smokers, the odds for major depressive disorder tended to
increase 1.47-fold for women who smoked 11–20 cigarettes per
day (P=0.094) and more than doubled for those who smoked
more than 20 cigarettes per day (P=0.003) (Table 2).
Being physically active was found to be protective against
major depressive disorder (age-adjusted OR=0.58, 95% CI 0.37–
0.91, P=0.017). None the less, the association between smoking
and major depressive disorder was not explained by differences
in physical activity. The independent relationships between
smoking and physical activity on the risk for major depressive
disorder are shown in Fig. 1. Alcohol consumption did not affect
this association.
Retrospective cohort study
Characteristics of women included in this analysis are shown in
Table 3. Among 87 women who were current smokers at baseline,
13 developed de novo major depressive disorder during 781
person-years of observation, whereas among 584 non-smokers,
38 developed major depressive disorder during 5384 person-years
of observation. Estimated rates of major depressive disorder were
16.6 (95% CI 9.7–28.7) per 1000 person-years for smokers and 7.1
(95% CI 5.1–9.7) per 1000 person-years for non-smokers.
Exposure to smoking was found to increase the risk for
developing a first episode of major depressive disorder by 93%,
hazard ratio (HR)=1.93 (95% CI 1.02–3.69, P=0.045). A
Kaplan–Meier survival plot showing the probability of remaining
free of major depressive disorder over a 10-year period for women
exposed and unexposed to smoking at baseline is shown in Fig. 2.
Adjustment for socio-economic status enhanced the risk (adjusted
HR= 2.01, 95% CI 1.03–3.93, P=0.042). Further adjustment for
alcohol consumption, physical activity or physical illness did not
attenuate this association.
Discussion
This study provides both cross-sectional and longitudinal
evidence consistent with the hypothesis that tobacco smoking is
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associated with major depression. Our cross-sectional data
demonstrate that exposure to smoking is associated with a 1.46-
fold increase in the odds for major depressive disorder. Further-
more, our findings are suggestive of a dose-dependent association,
with more than a two-fold increase in the odds of major depres-
sive disorder for heavy smokers compared with non-smokers.
With the advantage of temporal sequencing, our longitudinal data
demonstrate that smoking is associated with a near doubling of
risk for developing de novo major depressive disorder over a 10-
year period. These effects were independent of age and physical
activity, and not explained by alcohol consumption.
Other cross-sectional studies have reported increased odds
of depression in smokers,5,6 with results retaining statistical
significance after adjusting for other major risk factors.6 Prospec-
tive studies, although limited, have further strengthened the
suspected role of smoking in depression. In an 11-year
population-based longitudinal Norwegian study, the hazard ratio
for a first depressive episode increased with smoking in a dose-
dependent fashion, such that the heaviest smokers (exceeding 20
cigarettes per day) had over four times the risk of those who
had never smoked.7 Increased incidence of major depression in
smokers has been reported in other shorter studies,12,13 including
data from adolescents.14 Longitudinal studies have also shown a
reverse relationship, in which the presence of depression increased
the risk of smoking progression.12,13 Positive effects on psycho-
motor performance and enhanced craving, as demonstrated in a
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Table 1 Participant characteristics in the case–control study
Major depressive disorder
(n=165)
No major depressive disorder
(n=806) P
Age, years: median (IQR) 33 (26–45) 43 (29–59) 50.0001
Smokers, n (%) 73 (44) 269 (33) 0.008
Socio-economic status, n (%) 0.857
Quintile 1 (low) 23 (14) 125 (16)
Quintile 2 33 (20) 184 (23)
Quintile 3 41 (25) 183 (23)
Quintile 4 29 (18) 142 (18)
Quintile 5 39 (24) 172 (21)
Alcohol users, n (%) 28 (17) 144 (18) 0.784
Physically active, n (%) 31 (19) 168 (21) 0.551
Cardiovascular disease, n (%) 56 (34) 240 (30) 0.290
Diabetes, n (%) 11 (7) 48 (6) 0.727
IQR, interquartile range.
Table 2 Smoking frequency (number of cigarettes per day) and the risk for major depressiona
Cigarettes per day Unadjusted OR (95% CI) Age-adjusted OR (95% CI)
510 1.02 (0.56–1.88) 0.88 (0.48–1.64)
11–20 1.62 (1.04–2.52) 1.47 (0.94–2.32)
420 2.17 (1.31–3.58) 2.18 (1.31–3.65)
a. Non-smokers form the reference group.
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Fig. 1 Independent contributions of tobacco smoking and
physical activity to the risk for major depression. Non-smokers
who are physically active form the reference group.
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Fig. 2 Survival plot (Kaplan–Meier) showing the probability of
remaining free of de novo major depressive disorder over a
10-year period for smokers and non-smokers at baseline.
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physiological study,15 may be pertinent factors for this obser-
vation. Other studies have provided support for a third possibility,
that depression and smoking coexist as epiphenomena of a com-
mon underlying cause, such as genetic factors.16,17 The efficacy of
bupropion in the treatment of both depression and nicotine
dependence18 may indicate some commonality between the two
conditions on a neurochemical level.
Dopamine is one such factor, which is believed to have a dual
role in depression and in the mechanism of addiction. Neuro-
chemical studies of depression, particularly with psychomotor
retardation, reported an association with diminished dopamine
metabolism, as evidenced by decreased levels of cerebrospinal fluid
homovanillic acid.19,20 Reduced striatal dopamine function has
also been shown in dopamine D2 receptor neuroimaging binding
studies.21,22 Dopamine is regarded as the central neurotransmitter
of reward, and as having a key role in the reinforcement of the
pathways to addiction.23 Dysregulation of the dopaminergic
system in addictive states is also a plausible mechanistic pathway
to depressive vulnerability.24
Smoking-induced oxidative stress is another factor. Tobacco
smoke generates free radicals, causing lipid peroxidation,
oxidation of proteins and other tissue damage in smokers.25,26
Depression has been characterised by elevated markers of
oxidative stress27–29 that demonstrates a positive correlation with
depressive severity30 and a return to normal levels after
treatment.28,29 It seems plausible that depression could be among
the oxidative stress sequelae of smoking.
There are several strengths and potential weaknesses in our
study. The length of the follow-up period is a key strength,
especially when published longitudinal studies have rarely
exceeded a few years at most. Given that smoking effects insidious
biochemical changes that are naturally accommodated by the
body’s homeostatic responses, long-term sequelae such as
depression, cancers, cardiovascular and pulmonary diseases may
only be reliably demonstrated over an extended time frame. Recall
limitations may have affected our ability to accurately diagnose
the time of onset of depressive episodes and, in the case–control
analysis, the potential exists for differential recall bias of smoking
practices. However, as this study was nested within a larger
prospective study, the latter risk was minimised as exposure to
smoking had been documented prior to psychiatric interview.
Furthermore, documentation of exposure to smoking and
assessment of outcome were performed by different study
personnel. The duration of smoking prior to the onset of depres-
sion was unknown, precluding estimation of duration of exposure
on depression. Inconsistencies in the number of cigarettes smoked
per day may have resulted in misclassification of smoking
frequency in the case–control analysis but the apparent
dose-dependent association strengthens the notion that smoking
is a risk factor for major depression. Small numbers limited a
comparable investigation in the longitudinal analysis. Also in
the longitudinal analysis, changes in exposure status during
follow-up have not been identified. Finally, as in all
observational studies, there may be unrecognised confounding.
We relied on self-reported history of cardiovascular disease and
diabetes as indicators of physical illness that may be affected by
smoking status. However, we cannot exclude possible confound-
ing by unrecognised comorbidity as individuals were not clinically
screened for all potential physical illnesses. Physical activity and
alcohol consumption were explored as concomitant lifestyle
factors with a potential for confounding because physical activity
had been previously reported as protective against depression,31
whereas physical inactivity32–34 and alcohol misuse6 are regarded
as risk factors. In this study, alcohol consumption did not appear
to confound the association between smoking and depression;
however, we acknowledge that our criteria for alcohol consump-
tion may have been too broad to confidently exclude its
contribution. Other factors predisposing to depression, such as
personality traits, developmental and family history of depression,
IQ or stress, were not considered as these data were not available.
Within these limitations, however, our data corroborate
literature that reveals a malevolent role of smoking in depression
and suggest that greater efforts are required in targeting smoking
as a routine intervention.35 Depression’s status as a leading cause
of global disease burden,36,37 one that is not anticipated to yield in
the coming decades,36 can only underscore the potential impact of
any effective preventive measures.
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Table 3 Participant characteristics in the retrospective cohort study
Smokers (n=87) Non-smokers (n=584) P
Age, years: median (IQR) 39 (31–52) 50 (37–63) 50.0001
Major depressive disorder, n (%) 13 (15) 38 (7) 0.006
Socio-economic status, n (%) 0.001
Quintile 1 (low) 26 (30) 93 (16)
Quintile 2 19 (22) 137 (23)
Quintile 3 22 (25) 107 (18)
Quintile 4 6 (7) 114 (20)
Quintile 5 14 (16) 133 (23)
Alcohol users, n (%) 20 (23) 96 (16) 0.132
Physically active, n (%) 14 (16) 69 (12) 0.258
Cardiovascular disease, n (%) 20 (23) 220 (38) 0.006
Diabetes, n (%) 3 (3) 44 (8) 0.129
IQR, interquartile range.
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